Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Universal Chimeric Antigen Receptor-Modified AT19 Cells by Chengdu USino Technology Biology for Hematological Tumor: Likelihood of Approval
Universal Chimeric Antigen Receptor-Modified AT19 Cells is under clinical development by Chengdu USino Technology Biology and currently in Phase I...
Data Insights
Universal Chimeric Antigen Receptor-Modified AT19 Cells by Chengdu USino Technology Biology for Unspecified B-Cell Lymphomas: Likelihood of Approval
Universal Chimeric Antigen Receptor-Modified AT19 Cells is under clinical development by Chengdu USino Technology Biology and currently in Phase I...